Summarize this content to 2000 words in 6 paragraphs in Arabic
Cases of excessive hair growth in babies across Europe were linked to their parents’ use of minoxidil.
ADVERTISEMENTA total of 11 cases of “werewolf syndrome” have been identified in babies across Europe due to exposure to a hair-loss medication used by their parents, according to a new report.Hypertrichosis, commonly referred to as “werewolf syndrome,” is a rare condition characterised by the abnormal growth of excessive hair in areas other than the scalp. This hair growth, according to the US National Institute of Health (NIH), may cover the entire face and body or appear in smaller, localised patches.The report, which was conducted by the Pharmacovigilance Centre of Navarre (CFN) in Spain, found that a number of babies affected by this syndrome had a parent who was using a treatment containing minoxidil to treat baldness. Minoxidil is a medication designed to promote hair growth and slow hair loss in individuals experiencing baldness. It can be administered either orally or as a topical solution applied directly to the scalp.The initial case first came to light when the CFN investigated the situation of a baby who had progressively developed excessive hair growth on the back, legs, and thighs over the course of two months.According to the report, the baby’s father, who had been on leave from work for a month to care for his son, had been using a 5 per cent minoxidil solution topically to treat his baldness.Still, the report added that after discontinuing contact with the medication, the symptoms in the affected baby completely regressed.Babies’ skin is more sensitive than adultsThe CFN then conducted a review of similar cases using data from the Spanish Pharmacovigilance System and the European Medicines Agency’s (EMA) EudraVigilance databases. Their analysis revealed additional occurances with similar characteristics involving babies in Europe who had “werewolf syndrome” and whose caregivers were using topical minoxidil to treat baldness.The CFN suggested two possible ways minoxidil might have been transferred from the caregivers to the infants, either orally or through direct skin contact. Given that babies have thinner and more sensitive skin compared to adults, it is easier for topical medications to be absorbed into their bodies.Following these findings, the European Pharmacovigilance Risk Assessment Committee (PRAC) decided to update the product information for medications containing minoxidil. The revised leaflets now include warnings about the potential risk of excessive body hair growth in infants following contact with areas where minoxidil has been applied.
